Study of Enasidenib and Venetoclax in IDH2-Mutated Blood Cancers

Conditions:   Acute Myeloid Leukemia;   Relapsed Cancer;   Refractory Cancer;   IDH2 Gene Mutation Interventions:   Drug: Enasidenib;   Drug: Venetoclax Sponsors:   University Health Network, Toronto;   Celgene;   AbbVie Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials